🔔Bezos and Gates back Synchron in drive for brain implant breakthrough
LAST March, brain-computing interface expert Tom Oxley sat down to dinner with Amazon.com founder Jeff Bezos to talk about Oxley’s nascent company, Synchron That meal in Ojai, Calif, ended with something better than dessert: Bezos told Oxley that he wanted to invest in the business.
Synchron said on Thursday (Dec 15) it completed a US$75 million funding round, part of it from Bezos Expeditions.
The financing was led by ARCH Venture Partners, and includes a cheque from Gates Frontier, the venture investment arm of Microsoft co-founder Bill Gates, and others. Existing investors also participated, including Khosla Ventures – whose founder, Vinod Khosla, introduced Oxley to Gates.
Brain-computer interfaces, known as BCIs, can interpret and stimulate parts of the brain and are seen as a possible treatment for brain injuries. New investors approached Synchron “through the lens of making an impact in neurology in an area of need,” Oxley said in an interview. They “saw BCI as a future therapeutic.” About 100 million people globally have upper limb impairment, he said, and could benefit from the technology.
LAST March, brain-computing interface expert Tom Oxley sat down to dinner with Amazon.com founder Jeff Bezos to talk about Oxley’s nascent company, Synchron That meal in Ojai, Calif, ended with something better than dessert: Bezos told Oxley that he wanted to invest in the business.
Synchron said on Thursday (Dec 15) it completed a US$75 million funding round, part of it from Bezos Expeditions.
The financing was led by ARCH Venture Partners, and includes a cheque from Gates Frontier, the venture investment arm of Microsoft co-founder Bill Gates, and others. Existing investors also participated, including Khosla Ventures – whose founder, Vinod Khosla, introduced Oxley to Gates.
Brain-computer interfaces, known as BCIs, can interpret and stimulate parts of the brain and are seen as a possible treatment for brain injuries. New investors approached Synchron “through the lens of making an impact in neurology in an area of need,” Oxley said in an interview. They “saw BCI as a future therapeutic.” About 100 million people globally have upper limb impairment, he said, and could benefit from the technology.